IMA
ImageneBio Inc NASDAQ Listed Feb 27, 1998$6.00
+5.45%
vs $5.69
Mkt Cap $29.2M
52w Low $4.55
10.9% of range
52w High $17.90
50d MA $5.68
200d MA $6.76
P/E (TTM)
—
EV/EBITDA
—
P/B
0.2x
Debt/Equity
0.1x
ROE
-34.1%
P/FCF
-0.6x
RSI (14)
53.20
ATR (14)
$0.32
Beta
0.55
50d MA
$5.68
200d MA
$6.76
Avg Volume
31.4K
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
12526 High Bluff Drive, Suite 345, San Diego, CA 92130 · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | AMC | -1.45 | -0.62 | +57.2% | 6.07 | +3.1% | -1.0% | -0.2% | -1.5% | +4.9% | -2.9% | — |
| Nov 12, 2025 | AMC | -1.47 | -2.91 | -98.0% | 8.55 | -0.2% | -2.6% | -2.0% | -5.6% | -0.9% | -3.9% | — |
| Jul 24, 2025 | AMC | -0.14 | -0.06 | +57.1% | 16.44 | -91.6% | +4.4% | -4.6% | -7.1% | +0.6% | +17.1% | — |
| May 8, 2025 | AMC | -0.21 | -0.18 | +14.3% | 12.96 | +0.0% | +4.6% | +0.9% | +1.8% | -6.9% | +1.9% | — |
| Mar 6, 2025 | AMC | -0.19 | -0.18 | +5.3% | 17.16 | -0.7% | +0.7% | -2.1% | -2.1% | +0.7% | -2.2% | — |
| Nov 7, 2024 | AMC | -0.27 | -0.19 | +29.6% | 20.28 | +0.0% | +4.1% | -0.6% | +0.6% | -1.1% | -1.7% | — |
| Aug 8, 2024 | AMC | -0.31 | -0.27 | +12.9% | 19.56 | +0.0% | +0.0% | +0.6% | +2.4% | -0.6% | +0.6% | — |
| May 13, 2024 | AMC | -0.40 | -0.28 | +30.0% | 15.84 | +2.3% | +0.8% | +0.8% | +4.5% | +2.1% | -2.1% | — |
| Mar 12, 2024 | AMC | -0.41 | -0.41 | +0.0% | 16.68 | +0.7% | +1.4% | +3.5% | +7.5% | -4.5% | +0.0% | — |
| Nov 9, 2023 | AMC | -0.44 | -0.40 | +9.1% | 15.96 | -1.5% | +9.8% | +1.4% | -8.1% | +2.9% | +6.4% | — |
| Aug 10, 2023 | AMC | -0.48 | -0.44 | +8.3% | 54.48 | +1.1% | -5.3% | +0.9% | -2.8% | +0.5% | -2.1% | — |
| May 15, 2023 | AMC | -0.46 | -0.39 | +15.2% | 84.00 | -1.9% | -12.0% | +5.2% | -4.8% | +2.9% | -4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 25 | Wedbush | Maintains | Neutral → Neutral | — | $16.44 | $1.38 | -91.6% | +4.4% | -4.6% | -7.1% | +0.6% | +17.1% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.12 | $21.00 | -0.6% | -0.6% | +0.6% | -1.1% | -1.7% | -1.2% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.56 | $19.68 | +0.6% | +0.6% | +2.4% | -0.6% | +0.6% | +1.8% |
| May 29 | Wedbush | Downgrade | Outperform → Neutral | — | $15.96 | $18.72 | +17.3% | +25.6% | +7.2% | -1.1% | +0.6% | -2.2% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.96 | $18.72 | +17.3% | +25.6% | +7.2% | -1.1% | +0.6% | -2.2% |
| May 14 | Wedbush | Maintains | Outperform → Outperform | — | $15.84 | $16.20 | +2.3% | +0.8% | +0.8% | +4.5% | +2.1% | -2.1% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.00 | $18.36 | +2.0% | +0.0% | +4.0% | -3.8% | -1.3% | -2.7% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.52 | $17.28 | -1.4% | -4.8% | +1.4% | +3.5% | +7.5% | -4.5% |
| Jan 19 | Wedbush | Maintains | Outperform → Outperform | — | $19.68 | $20.40 | +3.7% | -7.3% | +3.3% | -10.8% | +0.0% | -7.9% |
| Jan 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.68 | $20.40 | +3.7% | -7.3% | +3.3% | -10.8% | +0.0% | -7.9% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.56 | $47.04 | -5.1% | -67.8% | +9.8% | +1.4% | -8.1% | +2.9% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.40 | $50.04 | -0.7% | +8.1% | -5.3% | +0.9% | -2.8% | +0.5% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $59.16 | $59.52 | +0.6% | -7.5% | -4.2% | -3.9% | +8.1% | -5.3% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $69.72 | $69.24 | -0.7% | +3.3% | +3.2% | -3.6% | -2.8% | +11.2% |
| May 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $84.00 | $82.44 | -1.9% | -12.0% | +5.2% | -4.8% | +2.9% | -4.1% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $51.60 | $49.81 | -3.5% | -4.4% | -10.0% | +13.5% | -10.2% | -2.4% |
| Mar 15 | Credit Suisse | Maintains | Outperform → Outperform | — | $50.52 | $48.60 | -3.8% | +1.0% | +1.2% | -4.4% | -10.0% | +13.5% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.04 | $30.00 | +3.3% | +0.4% | -8.2% | +12.1% | -5.6% | -5.5% |
| Nov 29 | Credit Suisse | Maintains | Outperform → Outperform | — | $29.04 | $30.00 | +3.3% | +0.4% | -8.2% | +12.1% | -5.6% | -5.5% |
| Nov 8 | Credit Suisse | Maintains | Outperform → Outperform | — | $27.60 | $31.20 | +13.0% | +0.0% | -4.3% | -3.6% | +0.0% | +4.2% |
| May 13 | Credit Suisse | Maintains | Outperform → Outperform | — | $44.88 | $46.92 | +4.5% | +0.0% | -2.4% | +9.9% | -7.2% | -0.5% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $81.60 | $91.44 | +12.1% | +7.4% | -4.2% | -2.7% | -4.9% | -4.0% |
| Dec 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $180.48 | $187.68 | +4.0% | -1.3% | -3.8% | -6.5% | +4.0% | -4.8% |
| Aug 13 | Credit Suisse | Maintains | Outperform → Outperform | — | $132.36 | $133.92 | +1.2% | -2.3% | +2.2% | +3.5% | -0.2% | -3.9% |
| Apr 20 | Jefferies | Maintains | Buy → Buy | — | $239.28 | $239.28 | +0.0% | -7.8% | +4.6% | +4.1% | +4.5% | +5.1% |
| Apr 20 | Credit Suisse | Maintains | Outperform → Outperform | — | $239.28 | $239.28 | +0.0% | -7.8% | +4.6% | +4.1% | +4.5% | +5.1% |
| Apr 20 | William Blair | Maintains | Outperform → Outperform | — | $239.28 | $239.28 | +0.0% | -7.8% | +4.6% | +4.1% | +4.5% | +5.1% |
No insider trades available.
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
IMA issued equity with a 19.99% ownership cap, likely a strategic investment that limits any single party's control while raising capital without triggering excessive dilution concerns for existing shareholders.
Apr 13
8-K
Unknown — 8-K Filing
A new executive with financial and operational leadership experience from biotech has joined Immunomedics, signaling potential management strengthening for operational efficiency and financial discipline.
Mar 17
8-K
Unknown — 8-K Filing
ImageneBio's full-year 2025 results filing suggests potential clinical progress or operational updates that likely triggered mandatory disclosure, making this critical for evaluating the biotech's pipeline advancement and cash runway before next funding needs.
Mar 10
8-K
ImageneBio, Inc. -- 8-K Filing
ImageneBio's 8-K filing confirms its SEC reporting status, though specific material events or corporate developments are not clearly detailed in this technical documentation reference.
Feb 17
Institutional (13F) — Top 18
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Blue Owl Capital Holdings Lp | 959,337 | $5M | Added | Mar 2026 |
| 2 | Rtw Investments, Lp | 334,445 | $2M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 325,155 | $2M | New | Mar 2026 |
| 4 | Bml Capital Management, Llc | 200,730 | $1M | Added | Mar 2026 |
| 5 | Citadel Advisors Llc | 124,345 | $622K | Added | Mar 2026 |
| 6 | Renaissance Technologies Llc | 81,696 | $408K | Added | Mar 2026 |
| 7 | Nano Cap New Millennium Growth Fund L P | 26,500 | $183K | New | Dec 2025 |
| 8 | Rangeley Capital, Llc | 32,590 | $163K | Added | Mar 2026 |
| 9 | Morgan Stanley | 21,542 | $149K | Added | Dec 2025 |
| 10 | Jane Street Group, Llc | 14,896 | $103K | New | Dec 2025 |
| 11 | Hrt Financial Lp | 13,909 | $69K | New | Mar 2026 |
| 12 | Prelude Capital Management, Llc | 12,990 | $65K | Reduced | Mar 2026 |
| 13 | Barclays Plc | 10,959 | $55K | Added | Mar 2026 |
| 14 | Ubs Group Ag | 5,428 | $27K | Added | Mar 2026 |
| 15 | Royal Bank Of Canada | 1,000 | $5K | — | Mar 2026 |
| 16 | Jpmorgan Chase & Co | 293 | $1K | Added | Mar 2026 |
| 17 | Wells Fargo & Company/mn | 41 | $205 | New | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 24 | $120 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 6
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 27,296 | $183K | Feb 2026 |
| 2 | iShares Micro-Cap ETF | 20,721 | $104K | Mar 2026 |
| 3 | Fidelity Series Total Market Index Fund | 7,299 | $49K | Feb 2026 |
| 4 | Fidelity Total Market Index Fund | 5,821 | $39K | Feb 2026 |
| 5 | Fidelity Nasdaq Composite Index Fund | 1,904 | $13K | Feb 2026 |
| 6 | Guggenheim Active Allocation Fund | 13 | $87 | Feb 2026 |
Valuation
Market Cap
$29.2M
Enterprise Value
-$39.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.22x
P/S
—
P/FCF
-0.61x
EV/EBITDA
—
Shares Out
4.9M
Financials (TTM)
Revenue
$0
Net Income
-$45.1M
EBITDA
-$51.6M
Free Cash Flow
-$47.8M
Op Cash Flow
-$47.8M
EPS Basic
$-10.76
EPS Diluted
$-4.64
EPS Forward
$-2.93
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$153.0M
Total Liab.
$19.8M
Total Equity
$133.1M
Cash
$75.8M
LT Debt
$7.0M
Book Value/Sh
$27.33
Debt/Equity
0.08x
Current Ratio
12.49
Quick Ratio
12.49
Returns & Growth
ROE
-34.1%
ROA
-29.6%
ROIC
-33.4%
Rev Growth YoY
-77.1%
EPS Growth YoY
-954.9%
Price Returns
2W
-0.5%
1M
-2.3%
3M
-12.5%
6M
-14.8%
12M
-58.8%
Technicals
52W High
$17.90
52W Low
$4.55
50d MA
$5.68
200d MA
$6.76
RSI (14)
53.20
ATR (14)
$0.32
Beta
0.55
Avg Volume
31K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$1.33
High
$1.33
Low
$1.33
Median
$1.33
Data updated apr 25, 2026 3:14pm
· Source: financialmodelingprep.com